The process of repurposing drugs for new indications is a time- and cost-efficient approach with a higher success rate than developing new orphan drugs, thus significantly reducing the risk of drug development for rare diseases. Our company has an integrated technology platform to offer customers drug repositioning services and screening services of these compounds for new therapeutic purposes, accelerating the development of new therapies for rare diseases.

Drug Repurposing Screening for Rare Diseases

There are approximately 7,000 identified rare and neglected diseases, the vast majority of which lack effective treatments. The development of new treatments for rare diseases is a major challenge because the drug discovery process is often laborious, expensive, and prone to failure, it is particularly unappealing for rare diseases that affect only a small number of people and thus generate reduced profits. Drug repurposing has been proposed as an alternative strategy for the development of new therapies, particularly in the field of rare diseases. It offers lower risks, lower costs, and shorter timescales than the development of novel orphan drugs.

Drug repurposing, also known as drug repositioning or drug reprofiling, is the process of redeveloping compounds for use in different diseases. The strategy is based on the scientific principles that a single drug often interacts with multiple targets or pathways, and multiple drugs may act on the same target or pathway. With the Human Genome Project providing a wealth of genetic information on many rare diseases, including gene regulation, protein structure, and drug-target interactions, scientists have the opportunity to make breakthrough achievements in the field of drug repurposing.